Lexicon Prescribed drugs unveiled its fourth quarter and full-year 2025 monetary outcomes alongside vital pipeline developments through the latest earnings convention name.3941
Monetary Outcomes
Complete revenues reached $5.5 million in This autumn 2025, comprising $4.3 million in licensing income from the Novo Nordisk settlement and $1.1 million in internet gross sales of INPEFA. Full-year revenues totaled $49.8 million, together with $45 million upfront from Novo Nordisk and $4.6 million from INPEFA gross sales.3941
Internet loss narrowed to $15.5 million, or $0.04 per share, in This autumn in comparison with $33.8 million, or $0.09 per share, within the prior 12 months quarter. For the total 12 months, internet loss improved to $50.3 million, or $0.14 per share, from $200.4 million, or $0.63 per share.39
Analysis and growth bills dropped to $11.3 million in This autumn from $26.7 million, whereas promoting, basic, and administrative prices fell to $8.8 million from $32.3 million. Full-year working bills declined sharply to $98.7 million from $228.2 million.41
Money Place and Steerage
Money, investments, and restricted money stood at $125.2 million as of December 31, 2025. The corporate bolstered its place with $96.7 million from a February 2026 capital elevate and a $10 million milestone from Novo Nordisk.39
For 2026, Lexicon guides complete working bills at $100-110 million, with R&D at $63-68 million excluding pilavapadin Section 3 trials and SG&A at $37-42 million.41
Pipeline Updates
Sotagliflozin (INPEFA) advances in hypertrophic cardiomyopathy (HCM) with SONATA-HCM Section 3 enrollment surpassing 50%, focusing on completion mid-2026 and topline information in Q1 2027. The trial spans 130 websites throughout 20 international locations for obstructive and non-obstructive HCM.3941
ZYNQUISTA for sort 1 diabetes stays on observe for 2026 NDA resubmission utilizing STENO1 research information. Viatris progresses ex-U.S./Europe approvals, with first shipments to UAE.41
LX9851, licensed to Novo Nordisk for weight problems, accomplished IND-enabling research, triggering a $10 million milestone with potential for $20 million extra in 2026.39
Pilavapadin (LX9211) for diabetic peripheral neuropathic ache cleared FDA Finish-of-Section 2, paving manner for 2 Section 3 trials. Partnership discussions proceed.41
Govt Commentary
“The fourth quarter of 2025 marked the completion of an unimaginable 12 months for Lexicon,” acknowledged Mike Exton, Ph.D., Chief Govt Officer. “We have now begun 2026 with large momentum.”39
Scott Coiante, Senior Vice President and Chief Monetary Officer, added, “Our latest capital elevate and milestone fee resulted in additional than $100 million in extra money, offering the monetary footing wanted to assist our pipeline applications.”39
